To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID® (thalidomide), REVLIMID® (lenalidomide), lenalidomide and POMALYST® (pomalidomide). The THALOMID REMS® program, Lenalidomide REMS program and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Celgene-administered REMS programs, please click on the program name below: